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Abstract
Background: Allergic rhinitis (AR) is one of the most common allergic diseases. The conventional treatments of
allergic rhinitis are oral anti-histamines, the use of intranasal corticosteroids, and immunotherapy. Dissatisfied with
the ineffectiveness and side effects of these treatments, substantial numbers of patients are turning to alternative
treatments like Chinese herbal medicine, particularly Tian Jiu (TJ). TJ is a form of moxibustion in which herbal
patches are applied to specific acupoints on the skin. This study aims to investigate the efficacy and safety of TJ in
the treatment of allergic rhinitis.
Methods/design: This will be a prospective, randomized, single-blinded, controlled trial in patients with AR. After a
1-week run-in period, eligible subjects will be randomly assigned to the TJ group, placebo-control group or
waitlist-control group. The TJ and placebo-control groups will undergo a 4-week treatment with one session per week
and one 4-week post-treatment follow-up. Participants in the waitlist-control group will not receive any treatment
during the first 4 weeks but will be required to be assessed. The primary outcome will be the change in the weekly
average of the Total Nasal Symptom Score recorded from baseline to the end of treatment. The secondary outcomes
will be change in symptoms and change in need for medication between baseline and the end of treatment by using
the Rhinitis Quality of Life Questionnaire. Rescue medication (RM) needs will be measured using an RM score,
comprising the weekly sum of daily assessments and any form of systemic steroids for allergic rhinitis.
Discussion: This study will be the first study to compare TJ treatment for allergic rhinitis with a placebo-control group,
and a waitlist-control group. The investigation of TJ for allergic rhinitis will also suggest recommendations for clinical
practice. The results of this study are expected to provide consolidated evidence for the effectiveness and safety of TJ
for the treatment of patients with allergic rhinitis.
Trial registration: NCT02470845 (17 May 2015).
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Background
Allergic rhinitis (AR), which can be acute or chronic, is
one of the most common allergic diseases. A number of
surveys have documented the high prevalence of AR and
the substantial burden to patients and the health care
system [1–3]. In the United States, the prevalence of AR
was shown to vary from 10 to 30 % [4]. In Europe, the
prevalence was around 23 % [5]. In 11 cities in China,
the prevalence of AR was shown to vary from 8 to 24.1
% [6]. The conventional treatment of AR symptoms,
such as nasal obstruction, rhinorrhea, sneezing, and
itching, includes the use of intranasal corticosteroids,
oral anti-histamines with or without decongestants, im-
munotherapy, and education [7]. Substantial numbers of
patients with AR are dissatisfied with conventional med-
ical treatment and repeatedly experience side effects. As
a result, many AR sufferers are turning to complemen-
tary and alternative treatments [8, 9]. Among them,
Chinese medicine, including herbal medicine, acupunc-
ture and Tian Jiu (TJ), are frequently used to manage AR
in East Asia [10].
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In China, traditional Chinese medicine (TCM) has a
long history of using TJ as a measure to prevent asth-
matic attacks [11]. TJ as an external application is also
known as “drug moxibustion” or “vesiculating moxibus-
tion.” Herbal patches are applied on the selected acu-
points or the diseased part. In TCM, this treatment
regulates the functions of channels and zang-fu organs.
It can warm the channels and disperse coldness. It is
also able to invigorate qi movement, harmonize nutrient
absorption and defense mechanisms, and resolve stag-
nation in the body and stasis of the blood. The mecha-
nisms of TJ, which have been studied in recent years,
show that it can inhibit the release of mast cell media-
tors and modulate serum IgE levels, lymphocyte and/or
macrophage activity [12].
Currently, some clinical studies have showed that TJ
therapy is effective in treating AR. They have found that
TJ therapy is better than placebo for treating clinical
symptoms and signs as well as improving quality of life
[13, 14]. One previous study has also shown that the TJ
group had lower scores for sneezing, rhinorrhea and
nasal stuffiness after finishing therapy when compared
with the control group and also showed significant im-
provement in the scores for the 36-item Short Form
Health Survey (SF-36), which measures patients’ quality
of life [15]. A study using the Rhinitis Quality of Life
Questionnaire (RQLQ) to assess quality of life also dem-
onstrated that TJ therapy can improve quality of life
when compared with a placebo group [16].
In recent years, clinical and basic researchers have
found that TJ acts as a modulator of anti-inflammatory
cytokines [17] and affects neuro-immunological mecha-
nisms, e.g., lowering plasma levels of vasoactive intes-
tinal peptides and substance P [18]. However, these
studies were done on a relatively small scale and did not
use a randomized control design.
In order to further investigate the efficacy of TJ in the
treatment of AR, a rigorous randomized controlled trial
will be conducted in our clinical centers. The evidence
from this rigorous clinical research, if successful, will be-
come the basis for a large multi-center study. The over-
all goal is to develop evidence-based clinical guidelines
for the use of TJ therapy in treating AR.
The research was supported by the Marcoda Co. Ltd.
Research Fund and was registered with the identifier
NCT02470845 (17 May 2015) at ClinicalTrials.gov. The
funding agency had no role in the development of the
study design, data collection, or manuscript preparation
for publication.
Objective
The aim of this study is to investigate the efficacy of TJ in
the treatment of AR, by comparing it with a placebo-
control group and a waitlist-control group, in Hong Kong.
Methods/design
Study design
This will be a prospective, randomized, single-blinded,
controlled trial in patients with AR. After a 1-week run-
in period, eligible subjects will be randomly assigned to
the TJ group, placebo-control group or waitlist-control
group. Except for rescue medication (RM) drugs, no
other routine medication use for AR symptom control
will be permitted in the entire study.
The TJ group will undergo a 4-week treatment with
herbal patches for one session per week, and a 4-week
post-treatment follow-up of one assessment session per
week. The placebo-control group will undergo a 4-week
treatment with placebo patches for one session per
week, and a 4-week post-treatment follow-up of one as-
sessment session per week. The waitlist-control group
will receive no treatment during the first 4 weeks but,
beginning at the fifth week, this group will receive TJ
treatment for 4 weeks as compensatory. All groups will
be assessed in the same way throughout the study
period. The total study period will be 9 weeks. The par-
ticipant flowchart is listed in Fig. 1 and participant time-
line is listed in Fig. 2.
The study protocol has been approved by the Hong
Kong Baptist University Ethics Committee on the Use of
Human Subjects for Teaching and Research (Approval
number HASC/13-14/0241), and informed consent was
obtained from each participant.
Participants
Setting
The study will be conducted in the research and clinical
centers, School of Chinese Medicine, Hong Kong Baptist
University (HKBU). All participants will be recruited
from the general public via daily outpatient services and
advertisements in newspapers and on a website.
Inclusion criteria
Patients who have intermittent or persistent AR, who
are 18 years of age or older, regardless of gender, race or
educational and economic status will be included. The
diagnostic criteria for AR for inclusion will be as follows
according to the ARIA criteria [19]: (1) positive skin
prick tests, (2) high circulating levels of allergen-specific
IgE antibody detected by a specific blood test for allergy
called a radioallergosorbent (RAST) test, (3) clinical his-
tory or identified allergen, (4) nasal provocation (test).
The lowest score of the Total Nasal Symptom Score
(TNSS) should be 8 or above.
Exclusion criteria
Exclusion criteria will be allergic asthma, moderate to
severe atopic dermatitis, any autoimmune disorder, any
severe chronic inflammatory disease, history of anaphylactic
Kun et al. Trials  (2016) 17:248 Page 2 of 8
reactions and hypersensitivity to cetirizine or related drugs,
specific immunotherapy during the past 3 years or planned
in the next 2 years, and pregnancy or breastfeeding.
Interventions
Medications
Participants in the TJ group will be treated with herbal
patches on five acupoints on the back. The formula of
the herbal patch consists of Bai Jie Zi (Sinapis semen),
Yan Hu Suo (Corydulis rhizoma), Zhi Gan Sui (Kansui
radix), Xi Xin (Asari radix et rhizama) and Rengong She
Xiang (Moschus artifactus). The first four of these herbs
will be ground into a powder, mixed thoroughly with 20 %
Bai Jie Zi (Sinapis semen), 25 % Yan Hu Suo (Corydulis
rhizoma), 15 % Zhi Gan Sui (Kansui radix), and 40 % Xi
Xin (Asari radix et rhizama), and the resulting powder
will then be mixed with fresh ginger juice in a ratio
of 20 g to 25 ml. The mixture will be made in to a 1 cm2
round patch weighing 2 g. Artificial Rengong She Xiang
(Moschus artifactus), 0.02 g, will then be placed on top of
each patch. Participants in the placebo-control group will
be treated with placebo patches on the same acupoints as
the TJ group. The placebo patch consists of flour and ed-
ible pigments. These two ingredients will be mixed with
Fig 1 Participant flowchart
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water and made in to 1 cm2 round patches weighing 2 g.
Participants in the waitlist-control group will wait for 4
weeks and will not receive any treatment material. The
composition and the action of each herb in the TJ herbal
patches are listed in Table 1.
Acupoints
The choice of acupoints was based on a literature review
and clinical practice. A survey conducted in 2010 by the
School of Chinese Medicine at HKBU revealed that 60 %
of patients who were suffering from AR or asthma found
their symptoms were alleviated after receiving TJ ther-
apy. Amongst the 812 people receiving TJ therapy, 558
(approximately 70 %) were suffering from AR or asthma.
The survey covered 224 AR patients and 57 asthma pa-
tients, and found that 60 % of each group reported that
their symptoms were relieved [20]. The latest clinical
study conducted in 2014 revealed that more than 50 %
of patients suffering from AR obtained benefit after re-
ceiving TJ therapy. The study found that, among the
3438 patients included in the survey, 52–67 % of the pa-
tients with AR found that their symptoms were allevi-
ated and 32–50 % of those surveyed reported that their
body constitution had been improved [21].
Five acupoints will be used: Dazhui (GV 14), Feishu
(UB 13) and Shenshu (UB 23), on both sides of the body.
A TJ patch will be applied to each acupoint, and left on
for 2 hours. A 4 cm2 piece of hypoallergenic tape will be
used to stick one patch on one acupoint. After 2 hours
the patches will be removed by our Chinese medicine
practitioner (CMP). If a participant cannot tolerate the
stimulation or suffers a allergic reaction, the patching
time can be appropriately shortened. Names and details
of acupoints are listed in Table 2.
Outcomes
The primary outcome will be the change in the weekly
average of the Total Nasal Symptom Score (TNSS) re-
corded in participants’ diaries from baseline to the end
of treatment [22]. The TNSS consists of four nasal
symptoms (rhinorrhea, nasal itching, nasal obstruction,
and sneezing) using a five-point scale from 0 to 4 (0 =
no symptom, 1 =mild, 2 = moderate, 3 = severe, 4 = very
severe). The TNSS will be obtained from the sum of all
four individual symptom scores, with a total possible
score ranging from 0 (no symptoms) to 16 (maximum
symptom intensity). This scoring system has been vali-
dated [23, 24].
Fig 2 Schedule of enrollment, intervention and assessment
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The secondary outcomes will be changes in symptoms
and changes in need for medication between baseline and
the end of treatment. Symptoms will be assessed by using
the RQLQ, which has 28 questions in seven domains (ac-
tivity limitation, sleep problems, nasal symptoms, ocular
symptoms, other symptoms, practical problems, and emo-
tional function) ranked from 0 (no impairment) to 6 (se-
vere impairment) [25]. Rescue medication need will be
measured using an RM score (RMS), comprising the
weekly sum of daily assessments. Rescue medicine usage
will be scored daily on a four-point scale (0 = no rhinitis
medicine; 1 = cetirizine, 10 mg/d, or equivalent; 2 = cetiri-
zine, 20 mg/d, or equivalent; 3 = systemic or topical corti-
costeroids for AR) (daily range; 0 to 3; weekly range: 0 to
21). If more than one RM is used on the same day, only
the maximal score medication will be recorded [26].
For safety concern, we will record every adverse event
during the treatment and follow-up, and make statistical
comparisons. Treatment will be suspended immediately
should serious adverse events occur. Further assessment
will be needed to decide whether the trial should be
suspended.
Randomization assignment
This study is designed as a randomized, waitlist-control
trial. Eligible participants will be randomly and equally
allocated to one of the three groups: T (TJ) group, P
(placebo) group, and W (waitlist-control) group. Ran-
dom Allocation Software (version 1.0.0, Isfahan, Iran)
will be used to generate a randomization scheme. The
principal investigator (PI) will generate the random allo-
cation sequence, and will not share it with other
Table 1 Composition and action of Tian Jiu (TJ) herbal patches
Ingredients Percent Action
Sinapsis semen 8.79 TCM: 1. To warm the lung and sweep phlegm, 2. To disinhibit qi, 3. To dissipate binds and unblock
collaterals to relieve pain
Pharmaceutical study: 1. Antibacterial effect, 2. Skin stimulating effect, 3. Effect on gastric secretion,
4. Emetic effect, 5. Regulation of blood pressure, 6. Anti-lipid peroxidation, 7. Expectorant effect
Corydulis rhizoma 11.01 TCM: 1. To activate blood, 2. To move qi, 3. To relieve pain
Pharmaceutical study: 1. Effect on the CNS (analgesic effect, hypnotic effect, sedative and
tranquilizing effects), 2. Muscular relaxant effect, 3. Cardiovascular effect, 4. Effect on gastric
secretion and on urination, 5. Effect on pituitary-adrenocortical function
Kansui radix 6.56 TCM: 1. To expel retained fluid by purgation, 2. To disperse swelling and dissipate binds
Pharmaceutical study: 1. Purgative effect
Asari radix et rhizama 17.69 TCM: 1. To dispel wind and dissipate cold, 2. to dispel wind and relieve pain, 3. To open the
orifices, 4. To warm the lung and resolve fluid retention
Pharmaceutical study: 1. Sedative and analgesic effects, 2. Antipyretic and anti-inflammatory
effects, 3. Respiratory effect, 4. Cardiovascular effect, 5. Anti-histaminic and anti-allergic effects
Moschus Artifactus 0.45 TCM: 1. Induce resuscitation and restore consciousness, 2. Promote blood circulation to remove
obstruction, 3. Alleviate pain
Pharmaceutical study: 1. Effects on the CNS, 2. cardiovascular effects, 3. Anti-inflammatory effect,
4. Effects on the uterus
Zingiberis rhizoma recens
(fresh ginger juice)
55.5 TCM: 1. To release the exterior and dissipate cold, 2. To warm the middle energizer to check
vomiting, 3. To resolve phlegm and suppress cough, 4. To reduce toxin of fishery product
Pharmaceutical study: 1. Effects on the digestive system, 2. Anti-emetic effect, 3. Effect on the CNS
CNS central nervous system TCM traditional Chinese medicine
Table 2 Acupoints used in the study
Name of acupoints Areas Special qualification Effects of stimulation Indications
Dazhui (GV 14) In a depression below the
processus spinosus of the
7th cervical and above the
1st thoracic vertebrae
A crossing point by
which the leading sinartery
communicates with all
yang conduits
Stabilising and regulating the
qi of centre; strengthening the
hepatic and pulmonal orb, keeping
the nasal passages open
Cough and asthma
Feishu (UB 13) 1.5 cun laterally of the




for the pulmonal orb
Stabilising and harmonizing the
pulmonal and the renal orb;
regulating the qi; strengthening
the yin
Cough with asthma, common
cold, nasal congestion
Shenshu (UB 23) 1.5 cun laterally of the 2nd
lumbar vertebrae
Dorsal inductor of the
renal orb
Strengthening and harmonizing
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investigators. After the run-in stage, a research assistant
(RA) will assign treatments according to the codes
which are kept in opaque sealed envelopes with con-
secutive randomization numbers. Emergency unblinding
can only happen when the intervention information is
compulsory for the participant’s future management.
Sample size
Sample size calculations are based on the primary out-
come measurement. Since this is a pilot clinical study,
the improvement rate of group W would obviously be 0.
Subsequently, we assume that there will be 30 % im-
provement of TNSS symptoms in group T and 15 % in
group P. Considering a power of 80 %, and a alpha value
of 2.5 % (two-tailed), the sample size will be calculated










The λ is the cut-off value. Pt is 30 % and Pw is 0. Then
each group will need at least 38 subjects for significance
to be detected [27]. Allowing for a 20 % dropout, we
plan to recruit 46 subjects in each group, making a total
of 138.
Data processing and analysis
All efficacy and safety analyses will be conducted accord-
ing to the intention-to-treat (ITT) principle. Missing
values will be imputed by the last-observation-carried-
forward method. The statistical analysis will be per-
formed using the Statistical Packages for the Social Sci-
ences (SPSS) for Windows, version 21.0. Statistical
significance is defined as a two-sided P value of <0.05.
Baseline characteristics will be reported as mean (SD).
Comparisons between groups will be conducted by using
an analysis of covariance (ANCOVA) with baseline as
covariate. All items and subscales will be compared be-
tween groups for each 4-week period using ANCOVA,
with treatment group as a factor in the model and base-
line as the covariate. The changes in scores from base-
line to the end-point of treatment will be tested using
repeated measure analysis of variance (ANOVA).
Within-group differences will be assessed using a paired
t test for normally distributed data and a Wilcoxon
signed-rank test for non-normally distributed data.
Data collection and handling of withdrawal and dropout
This is a 9-week clinical trial, in which subjects must
take TJ for 8 weeks, attend five assessment visits,
complete a set of questionnaires, and stop taking other
medications for symptom control. All collected informa-
tion will be input into a computer by a RA. In the
meantime, all the files will be stored in numerical order.
Participant files will keep in storage for 5 years.
Considering maximization of participants’ compliance,
we will firstly run a thorough consent process for all
subjects by interpreting the details of the trial schedule,
potential adverse events, and the responsibilities of re-
searchers and participants. In addition, before every visit,
a RA will contact the subject to re-confirm the schedule.
If a participant shows signs of wanting to withdraw, we
would try to understand the possible reasons and aim to
find the best option for encouraging the participant to
remain in the study.
Discussion
TJ, also known as natural moxibustion is a conventional
method of treating respiratory allergic diseases in TCM.
The procedure is convenient and inexpensive. Thou-
sands of people accept this treatment in China every
year. Laboratory study has found that natural moxibus-
tion treatment can reduce IgE and interleukin (IL)-4
levels in the plasma of asthmatic rats, as well as airway
inflammation [28]. Clinical studies have found that TJ
can modulate anti-inflammatory cytokines [17], and that
it appears to work by neuro-immunological mechanisms.
However, there have been no methodologically con-
trolled clinical studies confirming the efficacy of TJ
therapy.
Therefore, our team has designed this randomized,
single-blinded, controlled trial to evaluate the effective-
ness of TJ therapy for AR. To our knowledge, this will
be the first study to compare TJ therapy with a placebo-
control group, as well as a waitlist-control group.
We use pigmented flour mixed with water to make the
sham TJ treatment. However, some articles mention that
in many studies, sham acupuncture is equally effective
as acupuncture [29, 30]. Although the sham TJ does not
have the pharmacological effects, the operating proce-
dures still causes a pressing sensation to the skin. Be-
cause we use the same acupoints for both groups,
pressing these acupoints may create an effect like the
acupressure. Therefore, we have designed the study with
three groups. One group (group T) will receive trad-
itional TJ therapy, which means the application of herbal
patches to specific acupoints on the skin. A second
group (group P) will receive sham TJ therapy, which
means the application of patches with an inert, similar
appearance to the TJ patch on the same acupoints. A
third group (group W) will not receive any treatment
material in order to examine the influence of sham TJ
on the study results.
The trial protocol is the foundation of every clinical
study. To facilitate appropriate reference standards for
scientific, ethical and safety issues before the trial begins,
the protocol of this study has been developed according
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to Consolidated Standards of Reporting Trials (CON-
SORT) statement [31], the Standard Protocol Items:
Standards for Reporting Interventions in Controlled Tri-
als of Acupuncture (STRICTA) statement 2010 [32], and
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) statement 2013 [33].
The results of this study are expected to provide con-
solidated evidence for the effectiveness and safety of TJ
for the treatment of patients with AR.
Trial status
At the time of manuscript submission the study is pre-
paring to enroll participants; no patient has yet begun
treatment.
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